2005P-0167
CP 1
Volume 1

Citizen Petition

Tab 1 - See, e.g., Comments of Bob Hugin, CFO, Celgene Corp., at the Lehman Bros. Global Health Care Conf. Published Material

Tab 2 - Celgene's 2003 Annual Report Published Material

Tab 3 - RADAR Paper (DRAFT dated March 5, 2005)

Tab 4 - Celgene Corp. website Thalomid (www.celgene.com/Products.aspx?s=1) Published Material

Tab 5 - Thalidomide Pharmion Information Brochure, January, 2004

Tab 6 - Comments of Dr. Alan Lewis, Pres, Celgene San Diego, at the JMP secs. LLC Research Conf. (March 2, 2005) Published Material

Tab 7 - Comments of John Jackson, CEO, Celgene Corp., at the Smith Barney Citigroup Healthcare Conf. (March 30, 2005)

Tab 8 - Pannikar V., The Return of Thalidomide: New Uses and Renewed Concerns, World Health Org., Pharmaceuticals Newsletter, 2003, 2:11 Published Material

Tab 9 - Centers of Disease Control Disease Info., Hansen's Disease (Leprosy)

Tab 10 - The News Hour with Jim Lehrer, Return of Thalidomide (PBS television broadcast, Aug. 4, 1998) Published Material

Tab 11 - Pan Am. Health Org., No Role of Thalidomide in Leprosy (www.paho.org/English/AD/DPC/CD/thalidomide.htm) Published Material

Tab 12 - Celgene Corp Form 10-K/A, p. 35 (Filed March 21, 2005)

Tab 13 - V. Chaudhry, MD et al, Thalidomide-Induced Neuropathy, Neurology 59: 1982 (2002) Published Material

Tab 14 - Zangari M., Anaissie E., Barlogie B. et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy, Blood 2001; 98: 1614-1615 Published Material

Tab 15 - Figg W, Arlen P, Gulley J, et al. A Randomized Phase II Trial of Docetaxel (Taxotere) Plus Thalidomide in Androgen-Independent Prostate Cancer, Semin Oncol. 2001 (August); 28 (suppl): 62-66 Published Material

Tab 16 - Physician's Desk Reference, 1095-99 (59th ed. 2005) Published Material

Tab 17 - How Drug's Rebirth as Treatment for Cancer Fueled Price Increases, Wall Street Journal, November 15, 2004 Published Material

Tab 18 - AWP Information